1. |
Potential therapeutic targets in Crohn's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Management of obesity discussed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Intervention reduces fluoxetine use and costs in managed care |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Use of statins poor in the ambulatory setting |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Metalloproteinase inhibitors: potential in cardiac hypertrophy? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Adjuvant therapy in stroke rehabilitation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 7-8
Cameron Johnston,
Preview
|
|
摘要:
Given that only 2-3% of patients with acute stroke in the US are treated with antithrombolytic therapy - it may be as high as 5-6% per cent in some teaching centres - it is an unfortunate reality that most patients emerge from the experience with at least some degree of deficit. This means that a significant part of the recovery from stroke will take place in the rehabilitation setting. At the annual meeting of the American Stroke Association [San Antonio, US; February 2002], stem cells, growth factors, amphetamines and even a drug used to treat Down's syndrome were all offered as potential adjuvants that could be used to aid rehabilitation of the stroke patient. However, whether these agents are truly useful is not clear from the data that were presented.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Ramipril: cardioprotective activity goes beyond BP reduction |
|
Inpharma Weekly,
Volume &NA;,
Issue 1327,
2002,
Page 11-12
Cameron Johnston,
Preview
|
|
摘要:
The 1999 HOPE (Heart Outcomes Prevention Evaluation) study represented a new paradigm in clinical trials for hypertension in that few, if any, trials prior to this had investigated hypertension in high-risk patients, specifically those who had already experienced a myocardial infarction or stroke or had significant cardiovascular/cerebrovascular disease.*Dr Jeffrey Probstfield, professor of medicine and epidemiology at the University of Washington, Seattle, US, discussed the HOPE study in a presentation at the annual meeting of the American Stroke Association [San Antonio, US; February 2002]. In particular, though, he expanded on one small sub-group analysis that could shed important light on why the results of the overall study turned out the way they did.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|